Neuropathic Pain - Pipeline Assessment and Market Forecasts to 2016 published by GlobalData in July, 2010. This report consists of Pages: 61 and the price starts from US $ 2000.
Abstract
Neuropathic Pain - Pipeline Assessment and Market Forecasts to 2016
Summary
GlobalData, the industry analysis specialist’s new report,
“Neuropathic Pain - Pipeline Assessment and Market Forecasts to
2016”, is an essential source of information and analysis on the global
neuropathic pain market. The report identifies the key trends shaping and
driving the global neuropathic pain market. The report also provides insight
into the prevalent competitive landscape and the emerging players expected to
bring significant shifts in the positioning of the existing market leaders.
Most importantly, the report provides valuable insights into the pipeline
products within the global neuropathic pain sector.
This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by
GlobalData’s team of industry experts.
GlobalData estimated the global neuropathic pain market to be valued at $4.8
billion in 2008. It is expected to grow at a Compound Annual Growth Rate
(CAGR) of approximately 4.3% from $4.8 billion in 2008 to $6.5 billion in
2015. This growth will be supported by the increase in the aging population,
increased treatment seeking behavior and increased uptake of the current
products. The diagnosis rate remains as one of the barriers for the growth of
the market. The available treatment options are moderately successful in
meeting the market demand. There is still a need for better therapy and there
exists unmet needs. There exists a market potential for any new entrant that
will cater for these unmet needs. There is enormous opportunity for any drug
that could match or better the efficacy provided by the current players with
increased safety.
Scope
The scope of the report includes:
- Annualized global neuropathic pain
market revenues data from 2001 to 2009, forecast forward for eight years to
2016.
- Pipeline analysis data providing a split across different phases,
mechanism of action being developed and emerging trends. Key classes of
mechanism of action include opioid receptor agonists, cannabinoid receptor
modulators, NMDA antagonists, protein kinase inhibitors, ion channel
targetters, serotonin norepinephrine reuptake inhibitors, adenosine agonists,
cytokine modulators, AMPA antagonists, nicotinic receptor agonists, TRPV1
receptor agonists, selective subtype sodium channel antagonists and iNOS/nNOS
dual inhibitors.
- Analysis of the current and future market competition
in the global neuropathic pain market. Key future market players covered are
NeurogesX, Cephalon Inc., UCB S.A., Newron Pharmaceuticals, EpiCept
Corporation, GW Pharmaceuticals, Johnson & Johnson, Avanir pharmaceuticals,
GlaxoSmithKline plc and AstraZeneca.
- Insightful review of the key
industry drivers, restraints and challenges. Each trend is independently
researched to provide a qualitative analysis of its implications.
- Key
topics covered include strategic competitor assessment, market
characterization, unmet needs and the implications for future market
associated with neuropathic pain.
Reasons to buy
The report will enhance your decision making capability in a more rapid and
time sensitive manner. It will allow you to:
- Develop and design your
in-licensing and out-licensing strategies through a review of the pipeline
products and technologies and by identifying companies with the most robust
pipeline.
- Develop business strategies by understanding the trends
shaping and driving the global neuropathic pain market.
- Drive revenues
by understanding key trends, innovative products and technologies, market
segments and companies likely to impact the global neuropathic pain market in
future.
- Formulate effective sales and marketing strategies by
understanding the competitive landscape and by analyzing the performance of
various competitors.
- Identify emerging players with potentially strong
product portfolio and create effective counter-strategies to gain the
competitive advantage.
- Organize your sales and marketing efforts by
identifying the market categories and segments that present the maximum
opportunity for consolidations, investments and strategic partnerships.
-
What’s the next big thing in the global neuropathic pain market
landscape? Identify, understand and capitalize.
Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2
Global Neuropathic Pain Market: Market Characterization 6
2.1 Overview
6
2.2 Neuropathic Pain Market Size 6
2.3 Neuropathic Pain Market
Forecast and CAGR 6
2.4 Drivers and Barriers for Neuropathic Pain Market
8
2.4.1 Drivers for Neuropathic Pain Market 8
2.4.2 Barriers for
Neuropathic Pain Market 8
2.5 Opportunity and Unmet Need 9
2.6 Key
Takeaway 10
3 Global Neuropathic Pain Market: Competitive Assessment
11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3
Product Profile for the Major Marketed Products in the Neuropathic Pain Market
12
3.3.1 Lyrica (pregabalin) 12
3.3.2 Cymbalta (duloxetine) 14
3.3.3 Lidoderm (lidocaine patch 5%) 15
3.3.4 Neurontin (gabapentin) 16
3.3.5 Qutenza (capsaicin) 8% Patch 17
3.4 Key Takeaway 20
4 Global
Neuropathic Pain Market: Pipeline Assessment 21
4.1 Overview 21
4.2
Strategic Pipeline Assessment 21
4.2.1 Technology Trends Analytic
Framework 21
4.3 Neuropathic Pain Therapeutics - Promising Drugs
under Clinical Development 23
4.4 Molecule Profile for Promising Drugs
under Clinical Development 24
4.4.1 Vimpat (lacosamide) 24
4.4.2
Fentora 25
4.4.3 Ralfinamide 26
4.4.4 NP-1 27
4.4.5 Sativex 28
4.5 Neuropathic Pain Therapeutics Market - Clinical Pipeline by
Mechanism of Action 29
4.6 Neuropathic Pain Pipeline - Pipeline by
Clinical Phases of Development 30
4.6.1 Neuropathic Pain Therapeutics
- Regulatory Filing and Phase III Clinical Pipeline 31
4.6.2
Neuropathic Pain Therapeutics - Phase II Clinical Pipeline 32
4.6.3
Neuropathic Pain Therapeutics - Phase I Clinical Pipeline 34
4.6.4
Neuropathic Pain Therapeutics - Preclinical Pipeline 35
4.6.5
Neuropathic Pain Therapeutics - Discovery Pipeline 35
4.7
Discontinued / Suspended Drugs for Neuropathic Pain 36
4.8 Key Takeaway
36
5 Global Neuropathic Pain Market: Implications for Future Market
Competition 37
6 Global Neuropathic Pain Market: Future Players in
Neuropathic Pain Market 39
6.1 Introduction 39
6.2 NeurogesX 40
6.2.1 Overview 40
6.2.2 Pain Portfolio 40
6.2.3 Neuropathic Pain
Product Portfolio 40
6.3 Cephalon Inc. 42
6.3.1 Overview 42
6.3.2
Pain Portfolio 42
6.3.3 Neuropathic Pain Product Portfolio 43
6.4 UCB
S.A. 44
6.4.1 Overview 44
6.4.2 Pain Portfolio 44
6.4.3
Neuropathic Pain Portfolio 44
6.5 Newron Pharmaceuticals 45
6.5.1
Overview 45
6.5.2 Pain Portfolio 45
6.5.3 Neuropathic Pain Product
Portfolio 46
6.6 EpiCept Corporation 47
6.6.1 Overview 47
6.6.2
Pain Portfolio 47
6.6.3 Neuropathic Pain Product Portfolio 47
6.7 GW
Pharmaceuticals 48
6.7.1 Overview 48
6.7.2 Pain Portfolio 48
6.7.3
Neuropathic Pain Product Portfolio 49
6.8 Johnson & Johnson Pharmaceutical
Research & Development, L.L.C. 50
6.8.1 Overview 50
6.8.2 Pain
Portfolio 50
6.9 Avanir Pharmaceuticals 51
6.9.1 Overview 51
6.9.2
Pain Portfolio 51
6.9.3 Neuropathic Pain Product Portfolio 51
6.10
GlaxoSmithKline Plc. 51
6.10.1 Overview 51
6.10.2 Pain Portfolio
51
6.10.3 Neuropathic Pain Product Portfolio 52
6.11 AstraZeneca
52
6.11.1 Overview 52
6.11.2 Pain Portfolio 52
6.11.3 Neuropathic
Pain Product Portfolio 53
7 Global Neuropathic Pain Market: Appendix
54
7.1 Market Definitions 54
7.2 Scope of Pipeline Research 54
7.3
Abbreviations 54
7.4 Research Methodology 55
7.4.1 Coverage 56
7.4.2 Secondary Research 56
7.4.3 Forecasting 57
7.4.4 Primary
Research 60
7.4.5 Expert Panel Validation 60
7.5 Contact Us 60
7.6
Disclaimer 60
7.7 Sources 61
1.1 List of Tables
Table 1:
Neuropathic Pain, Global, Market Revenues, 2001-2009 7
Table 2:
Neuropathic Pain, Global, Market Forecast, 2009-2016 7
Table 3:
Major Marketed Products Comparison in the Neuropathic Pain Market, 2010
19
Table 4: Neuropathic Pain Therapeutics - Most Promising Drugs
under Clinical Development, 2010 23
Table 5: Neuropathic Pain Therapeutics
- Regulatory Filing and Phase III Clinical Pipeline, 2010 31
Table
6: Neuropathic Pain Therapeutics - Phase II Clinical Pipeline, 2010
32
Table 7: Neuropathic Pain Therapeutics - Phase I Clinical
Pipeline, 2010 34
Table 8: Neuropathic Pain Therapeutics -
Preclinical Pipeline, 2010 35
Table 9: Neuropathic Pain Therapeutics
- Discovery Pipeline, 2010 35
Table 10: List of Discontinued Drugs
for Neuropathic Pain, 2010 36
Table 11: NeurogesX - Pain Marketed
Products, 2010 40
Table 12: NeurogesX - Pain Pipeline Products,
2010 40
Table 13: Cephalon Inc. - Pain Marketed Products, 2010
42
Table 14: Cephalon Inc. - Pain Pipeline Products, 2010 42
Table 15: UCB S.A. - Pain Pipeline Products, 2010 44
Table 16:
Newron Pharmaceuticals - Pain Pipeline Products,2010 45
Table 17:
EpiCept Corporation - Pain Pipeline Products, 2010 47
Table 18: GW
Pharmaceuticals - Pain Marketed Products, 2010 48
Table 19: GW
Pharmaceuticals - Pain Pipeline Products, 2010 49
Table 20: Johnson
& Johnson Pharmaceutical Research & Development, L.L.C. - Pain Marketed
Products, 2010 50
Table 21: Johnson & Johnson Pharmaceutical Research &
Development, L.L.C. - Pain Pipeline Products, 2010 50
Table 22:
Avanir Pharmaceuticals - Pain Pipeline Products, 2010 51
Table 23:
GlaxoSmithKline plc. - Pain Pipeline Products, 2010 52
Table 24:
AstraZeneca - Pain Pipeline Products, 2010 53
1.2 List of
Figures
Figure 1: Neuropathic Pain, Global, Market Revenues,
2001-2009 6
Figure 2: Neuropathic Pain, Global, Market Forecast,
2009-2016 7
Figure 3: Opportunity and Unmet Need in the Neuropathic
Pain Market, 2010 9
Figure 4: Strategic Competitor Assessment of the
Major Marketed Products in Neuropathic Pain, 2010 12
Figure 5: Technology
Trends Analytic Framework of the Neuropathic Pain Pipeline, 2010 21
Figure
6: Technology Trends Analytic Framework of the Neuropathic Pain Pipeline
- Description, 2010 22
Figure 7: Neuropathic Pain Therapeutics
Market - Clinical Pipeline by Mechanism of Action, 2010 29
Figure 8:
Neuropathic Pain Pipeline by Phase of Clinical Development, 2010 30
Figure
9: Implications for Future Market Competition in the Neuropathic Pain Market,
2010 37
Figure 10: Neuropathic Pain Therapeutics Market - Clinical
Pipeline by Company, 2010 39
Figure 11: GlobalData Methodology 56
Figure 12: GlobalData Market Forecasting Model 59
